Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / CytomX Therapeutics, Inc.

2014 · Co-Development · $1.2B · Terminated

BMS paid CytomX $50M upfront plus research funding and up to $298M per target in development, regulatory and commercial milestones across four oncology targets including CTLA-4. The deal validated CytomX's Probody masked-antibody platform and was later expanded to eight targets in 2017 (and again in 2021).

Key facts

• Announced May 27, 2014
• Closed Jun 25, 2014
• Deal value $1.2B
• Deal type Co-Development
• Therapeutic area Multiple cancers
• Indications Multiple cancers
• Key assets Probody therapeutics directed at CTLA-4 and three other oncology targets
• Mechanism Tumor-microenvironment-activated masked monoclonal antibodies (Probody platform)

← Browse all deals  ·  How we score deals